Candel Therapeutics (CADL) Total Non-Current Liabilities: 2020-2023
Historic Total Non-Current Liabilities for Candel Therapeutics (CADL) over the last 3 years, with Sep 2023 value amounting to $26.6 million.
- Candel Therapeutics' Total Non-Current Liabilities fell 5.83% to $26.6 million in Q3 2023 from the same period last year, while for Sep 2023 it was $26.6 million, marking a year-over-year decrease of 5.83%. This contributed to the annual value of $28.1 million for FY2022, which is 312.19% up from last year.
- As of Q3 2023, Candel Therapeutics' Total Non-Current Liabilities stood at $26.6 million, which was down 1.18% from $26.9 million recorded in Q2 2023.
- Candel Therapeutics' Total Non-Current Liabilities' 5-year high stood at $28.3 million during Q3 2022, with a 5-year trough of $5.5 million in Q3 2021.
- In the last 3 years, Candel Therapeutics' Total Non-Current Liabilities had a median value of $26.8 million in 2023 and averaged $21.0 million.
- As far as peak fluctuations go, Candel Therapeutics' Total Non-Current Liabilities skyrocketed by 411.57% in 2022, and later declined by 5.83% in 2023.
- Candel Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $6.0 million in 2020, then climbed by 14.50% to $6.8 million in 2021, then soared by 312.19% to $28.1 million in 2022, then fell by 5.83% to $26.6 million in 2023.
- Its Total Non-Current Liabilities stands at $26.6 million for Q3 2023, versus $26.9 million for Q2 2023 and $26.4 million for Q1 2023.